Appetite Regulation Peptides

A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.

A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.

The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions.

An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease.

A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026.

A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026.

The first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide.

A growth hormone secretagogue that also stimulates appetite through ghrelin receptor activation.

A 12-amino-acid peptide discovered via AI that suppresses appetite by acting on the hypothalamus, without nausea or muscle loss observed in animal models.

An ultra-long-acting injectable GLP-1 receptor agonist enabling monthly dosing, with 12.3% placebo-adjusted weight loss in Phase 2b and 10 Phase 3 trials planned.

A selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2.

An investigational oral and injectable GLP-1/GIP dual agonist showing 12.2% oral weight loss at 13 weeks at ECO 2026 and 14.7% injectable weight loss, with Phase 3 VANQUISH trials fully enrolled.

A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a.

Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1.

A once-weekly injectable GLP-1/GIP dual receptor agonist in Phase 3 trials for obesity, with an oral formulation in development and backed by a record-setting $625M biotech IPO.

An oral small-molecule GLP-1 receptor agonist discontinued by Pfizer in 2026 after a potential drug-induced liver injury signal, despite showing meaningful weight loss in Phase 2b.

A bispecific GIPR antagonist and GLP-1 receptor agonist antibody-peptide conjugate developed by Amgen for obesity and type 2 diabetes.

The first oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors for obesity treatment with muscle preservation.

A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) studied for enhanced weight loss through dual hormonal pathways.

A GLP-1/GIP/glucagon triple receptor agonist in Phase 2 development for type 2 diabetes and obesity, competing with retatrutide in the triple-agonist space.

A first-in-class peptide-drug conjugate that simultaneously activates five metabolic receptors (GLP-1R, GIPR, PPARα, PPARγ, PPARδ), published in Nature in April 2026 with preclinical results surpassing tirzepatide and triple agonists.

A new class of peptide-based weight loss therapeutics that act through the GFRAL/RET receptor in the brainstem, representing a non-GLP-1 mechanism for appetite suppression and energy expenditure regulation.

A cAMP signaling-biased GLP-1 receptor agonist approved in China for chronic weight management, with Phase 3 data showing up to 15.4% weight loss.

An oral non-peptide small-molecule GLP-1 receptor agonist achieving 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II, with Phase 3 on track for Q3 2026 after positive FDA end-of-Phase 2 feedback.

A newly discovered 12-amino acid anorexigenic peptide derived from the GDF15 prepropeptide region, representing a novel appetite-suppression pathway.

A next-generation once-monthly amylin receptor agonist peptide with a 32-day half-life and 91% greater weight loss than petrelintide in preclinical models. IND filing expected Q2 2026.

A next-generation once-monthly GLP-1R/GIPR dual agonist peptide with a 14-day half-life (6-fold longer than tirzepatide) and 71% greater weight loss than tirzepatide in preclinical models.

A next-generation once-monthly GLP-1R/GIPR/GCGR triple peptide agonist with 5-fold greater potency than retatrutide and a 17-day half-life enabling monthly dosing. IND filing expected Q2 2026.

A GIP/glucagon dual agonist that achieves weight loss comparable to retatrutide without GLP-1 receptor activity, potentially eliminating GI side effects. Published in Molecular Metabolism (April 2026).

A GLP-1/GIP co-agonist prodrug engineered for once-monthly dosing using MBX Biosciences' PEP platform. Phase 1 blinded data showed 7% mean weight loss at 8 weeks with minimal GI side effects.

A novel quadruple agonist prodrug combining GLP-1, GIP, glucagon, and DACRA (dual amylin and calcitonin receptor agonist) activity in a single molecule, designed for once-monthly dosing and superior efficacy.

A potential first-in-class triple GLP-1, GIP, and NPY2 receptor agonist peptide entering Phase 2 development mid-2026 for obesity, developed by Boehringer Ingelheim using Gubra-discovered technology.

A novel triple agonist peptide targeting GLP-1 and peptide YY receptors Y1 and Y2, designed to suppress appetite and improve glycemic control while avoiding GI side effects common to first-generation GLP-1 drugs.

A novel once-weekly GLP-1/glucagon dual receptor agonist showing rapid weight loss in Phase 1 trials with preserved lean body mass and direct liver benefits.

A once-daily GLP-1/glucagon dual receptor agonist studied for MASH, obesity, and type 2 diabetes with demonstrated liver fat reduction and antifibrotic activity.

A unimolecular GLP-1 and amylin receptor co-agonist developed by Novo Nordisk, available in both subcutaneous and oral formulations, with Phase 2 data showing up to 24.3% weight loss and Phase 3 AMAZE trials initiated in 2026.

A once-monthly injectable GLP-1 receptor agonist developed by Pfizer (acquired from Metsera), showing 12.3% placebo-adjusted weight loss in Phase 2b trials with a tolerability profile comparable to weekly semaglutide.

An oral once-daily small-molecule GLP-1 receptor agonist developed by Ascletis Pharma, showing 5.4–7.7% placebo-adjusted weight loss at 13 weeks in Phase 2, with in vitro potency 2–3x greater than orforglipron.

CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results.